Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol–sorafenib hybrids

Sorafenib is recommended as the primary therapeutic drug for patients with hepatocellular carcinoma. To discover a new compound that avoids low response rates and toxic side effects that occur in sorafenib therapy, we designed and synthesized new hybrid compounds of sorafenib and 2,4,5-trimethylpyri...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Bhuwan Prasad, Chaudhary, Prakash, Guragain, Diwakar, Jee, Jun-Goo, Kim, Jung-Ae, Jeong, Byeong-Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344761/
https://www.ncbi.nlm.nih.gov/pubmed/34340602
http://dx.doi.org/10.1080/14756366.2021.1953997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344761/
https://www.ncbi.nlm.nih.gov/pubmed/34340602
http://dx.doi.org/10.1080/14756366.2021.1953997

Ejemplares similares